Featured Research

from universities, journals, and other organizations

Blood Pressure Drug Shown To Cut Stroke, Death Risks In Common Form Of Hypertension

Date:
September 27, 2002
Source:
University Of Michigan Health System
Summary:
A drug that reduces high blood pressure in people with a form of the disease that's common later in life also cuts their risk of stroke and death, and does it better than another hypertension drug, a new study finds.

ANN ARBOR, MI – A drug that reduces high blood pressure in people with a form of the disease that's common later in life also cuts their risk of stroke and death, and does it better than another hypertension drug, a new study finds.

Related Articles


In the Sept. 25 issue of the Journal of the American Medical Association, an international team of researchers report that patients over age 55 who took a drug called losartan had a significantly lower combined rate of cardiovascular death, stroke and heart attack than similar patients taking an older drug called atenolol.

The results are from a substudy of the Losartan Intervention for Endpoint Reduction in Hypertension, or LIFE, study, co-led by physicians from the University of Michigan.

All 1,326 men and women in the study had isolated systolic hypertension, or ISH, a form of high blood pressure in which the "top number" in the reading is too high, but the bottom number is normal. The pumping chambers of the patients' hearts were also enlarged, a condition called left ventricular hypertrophy caused by hypertension.

ISH is the most common form of high blood pressure in middle-aged people and the elderly, but is much less likely to be controlled by medications. One in four Americans, about 50 million people, have some form of hypertension, many with no symptoms. Left uncontrolled, high blood pressure can damage the heart, kidneys and blood vessels, and lead to stroke, heart attack and heart failure.

In the study, the combined rate of cardiovascular death, stroke and heart attack in patients taking losartan was 25 percent lower than the risk for those taking atenolol. The rate of cardiovascular-related deaths was 46 percent lower for losartan patients, their rate of stroke was 40 percent lower, and their overall death rate was 28 percent lower. They also had a lower rate of new diabetes diagnosis during the study. Heart attack rates were similar between the two groups.

Both groups experienced a similar drop in blood pressure, and more than 40 percent of both groups were able to reduce their blood pressure to around 140/90 mm Hg.

"This is the first demonstration that a treatment can reduce illness and death in ISH patients better than another treatment that is equally good at reducing blood pressure," says author and LIFE study co-leader Stevo Julius, M.D., Sc.D. "The finding of a 40 percent reduction in stroke is especially important, because of stroke's role as a major cause of death and disability in people with hypertension." Julius is the Frederick G.L. Huetwell Professor of Hypertension and professor of Physiology at the U-M Medical School, and a member of the U-M Cardiovascular Center.

The study was funded by Merck & Co., which markets losartan by the name Cozaar.

The results, Julius continues, are further enhanced by the fact that patients experienced fewer negative side effects on losartan better than they did on atenolol. "This favorable combination of better prevention and higher tolerability may facilitate the choice of losartan as the first-line blood pressure medication in patients with ISH," he says.

U-M adjunct professor of internal medicine and hypertension specialist Sverre Kjeldsen, M.D., Ph.D., who is also chief of cardiology at the Ullevaal University Hospital in Oslo, Norway, is the study's lead author.

The new LIFE results add to previous evidence of losartan's ability to cut the combined risk of cardiovascular death, stroke and heart attack by 13 percent, and stroke risk by 25 percent, in people over age 55 with all forms of hypertension. Those results, from the full LIFE group of more than 9,000 patients in seven countries, were published in March by the LIFE study group.

Losartan, introduced in 1995, is a kind of drug called an angiotensin II antagonist, which blocks the effects of a substance called angiotensin II that increases blood pressure by constricting blood vessels and causing water to be retained.

The LIFE study, which began in 1995, pitted losartan against atenolol, a member of the beta blocker class of drugs, for a study that ended in September, 2001.

Patients in the study were aged 55 to 80 years, with systolic (top) blood pressure readings between 160 and 200 and left ventricular hypertrophy confirmed by an electrocardiogram. They were randomized to either drug, then followed for four or more years with regular visits and increased dosing of the drug toward a goal of a systolic reading of 140.

The study was designed to be prospective, multicenter, multinational, double-blind, double-dummy, randomized, active-controlled and parallel group to ensure the most reliable results. Participants were predominantly white, reflecting the populations of many of the countries from which they were drawn.

High blood pressure is defined as systolic pressure (top number) of 140 or higher, and/or diastolic pressure (bottom number) of 90 or higher for most people. Isolated systolic hypertension is defined as when the top reading is greater than or equal to 140 and the bottom number is less than 90. All blood pressure readings are given in millimeters of mercury, or mm Hg.

In addition to medications, people with ISH and other forms of high blood pressure should talk with their physicians about how exercise, weight loss, stopping smoking and cutting salt in their diets can help lower blood pressure and reduce their risks of cardiovascular diseases, diabetes and kidney disease.

Julius has served as a consultant for Merck and other pharmaceutical companies, and Kjeldsen has received honoraria from Merck and other companies. Several other co-authors are Merck employees.

LIFE Study home page: http://www.scandinaviancri.se/life/results/home.shtm

U-M Cardiovascular Center home page: http://www.med.umich.edu/cvc/


Story Source:

The above story is based on materials provided by University Of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan Health System. "Blood Pressure Drug Shown To Cut Stroke, Death Risks In Common Form Of Hypertension." ScienceDaily. ScienceDaily, 27 September 2002. <www.sciencedaily.com/releases/2002/09/020926065214.htm>.
University Of Michigan Health System. (2002, September 27). Blood Pressure Drug Shown To Cut Stroke, Death Risks In Common Form Of Hypertension. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2002/09/020926065214.htm
University Of Michigan Health System. "Blood Pressure Drug Shown To Cut Stroke, Death Risks In Common Form Of Hypertension." ScienceDaily. www.sciencedaily.com/releases/2002/09/020926065214.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins